Paul Tudor Jones Verona Pharma PLC Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Verona Pharma PLC stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 7,200 shares of VRNA stock, worth $449,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,200Holding current value
$449,208% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VRNA
# of Institutions
218Shares Held
70.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$399 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$348 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$211 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$195 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$195 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.8B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...